Guideline Treatment for Mild-to-Moderate Crohn's Disease
For mild ileocecal Crohn's disease, budesonide (controlled ileal release) is the preferred first-line therapy for up to 12 weeks, while systemic corticosteroids should be reserved for moderate disease or when budesonide fails, with treatment limited to no more than 8 weeks. 1
First-Line Pharmacologic Therapy
Budesonide for Mild Ileocecal Disease
- Budesonide is specifically recommended for mild ileocecal or right-sided ileocolonic Crohn's disease 1
- Maximum treatment duration: 12 weeks
- Equally effective as systemic corticosteroids for inducing clinical remission in this location
- Significantly fewer systemic side effects compared to conventional corticosteroids
- Not effective for maintenance therapy - do not continue beyond induction period
Systemic Corticosteroids for Moderate Disease
- Reserved for moderate-to-severe disease or when budesonide is inappropriate
- Maximum duration: 8 weeks 1
- Effective for induction but never use for maintenance
- Associated with significant adverse events, especially with repeated courses
Critical Early Assessment Strategy
Reassess at 2 weeks with clinical evaluation and fecal calprotectin 1:
- If limited or poor response → escalate to advanced therapy immediately
- Avoid repeated corticosteroid courses unless all other effective therapies have failed and surgery is not an option
- Early effective treatment is associated with sustained corticosteroid-free remission and avoidance of surgical interventions
Alternative and Adjunctive Dietary Approaches
Exclusive Enteral Nutrition (EEN)
- In adults, EEN achieves 45% remission rates but compliance is the major limiting factor 2
- Duration: 6-8 weeks as sole food source
- Per-protocol analysis shows no significant difference from corticosteroids when patients can tolerate it
- Formula type (elemental, semi-elemental, polymeric) does not affect effectiveness
- Consider only in highly motivated, compliant patients willing to accept liquid-only diet
Food-Based Diets (Emerging Evidence)
The Crohn's Disease Exclusion Diet (CDED) shows promise 2:
- 62% remission rate at Week 6 in mild-to-moderate disease
- 50% maintained remission to Week 24
- 35% achieved endoscopic remission
- Can be used alone or with partial enteral nutrition
- More palatable alternative to EEN
Mediterranean diet is recommended over Specific Carbohydrate Diet 2:
- Approximately 40% symptomatic remission as adjunct to medical therapy
- Easier adherence compared to other restrictive diets
When to Escalate to Advanced Therapy
Consider advanced immunosuppressive therapy at corticosteroid initiation if 1:
- Moderate-to-severe disease features present
- Previous treatment failures
- Aggressive disease trajectory
- Ongoing inflammation detected on monitoring (fecal calprotectin, intestinal ultrasound, MRE, ileocolonoscopy)
For patients requiring advanced therapy, vedolizumab is suggested as first-line 1
Common Pitfalls to Avoid
- Never use corticosteroids for maintenance - this is a hard contraindication 1
- Do not continue budesonide beyond 12 weeks - no maintenance benefit
- Avoid repeated corticosteroid courses - each course should trigger consideration of advanced therapy
- Do not use 5-aminosalicylates - they should not be used in Crohn's disease 3
- Monitor frequently - mild disease can have ongoing subclinical inflammation requiring therapy optimization
Monitoring Strategy
Regular assessment with multiple modalities 1:
- Fecal calprotectin
- Intestinal ultrasound
- MR enterography
- Ileocolonoscopy when indicated
This identifies patients with ongoing inflammation who appear clinically mild but require therapy escalation to prevent long-term complications and bowel damage.